Mitigating & treating radiation-induced CNS injury with ACE inhibitors & statins

缓解

基本信息

  • 批准号:
    7660462
  • 负责人:
  • 金额:
    $ 52.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

The central nervous system (CNS) is the most critical of all normal tissues for maintaining coordinated normal function. Following radiation exposure, the response of the CNS has been attributable to parenchymal and vascular damages including oligodendrocytes, neural progenitors, and endothelial cells. A dynamic process of radiation-induced death of target cells and subsequent secondary reactive inflammatory process is believed to lead to cell loss, tissue damage and functional deficits. Arguably of greater consequence than the physical damage is the psychological impact of CNS injury which could result in the loss of sight, paralysis or reduced cognitive function. The only investigational demonstration of pharmacological mitigation of CNS radiation damage was recently made by our group using the Angiotensin Converting Enzyme (ACE) inhibitor, ramipril (an FDA-approved drug). Of note, a reduction of injury assessed functionally and histopathologically was observed even when ramipril was administered weeks after the radiation exposure. This project is based on the hypothesis that the suppression of oxidative stress resulting from multi-cellular interactions through a network of pro-inflammatory mediators would mitigate radiation-induced brain injury by specific pharmacological treatment. Three classes of drugs are well known to suppress oxidative stress and two of them, ACE inhibitors and their receptor blockers and statins are widely used in various cardiovascular disorders in humans. The project aims to address specific therapeutic roles of three classes of drugs, ACE inhibitors and receptor blockers, statins, and SOD mimetics, in all phases of the brain injury, i.e., acute, early delayed, and late delayed reactions. The primary goal is to demonstrate their efficacy and to optimize the use of drug dosage and timing of the administration to mitigate and treat the radiation brain injury. End points for evaluation are cognitive functions, visual function, MRI for permeability of the blood brain barrier, and histopathological and proliferative changes for neurogenesis, vascular and glial cells, using single doses of whole brain radiation of the adult rats. The positive findings from the proposed study will be readily translatable in humans, since both ACE inhibitors and statins are widely used in a variety of cardiovascular disorders in the clinics. In summary, experimental studies suggest radiation-induced CNS injury can be treated. The goal of this project is to bring one or more of these experimental approaches into clinical practice.
中枢神经系统(CNS)是所有正常组织中维持协调正常功能的最关键组织。辐射暴露后,CNS的反应归因于实质和血管损伤,包括少突胶质细胞、神经祖细胞和内皮细胞。辐射诱导的靶细胞死亡和随后的继发性反应性炎症过程的动态过程被认为导致细胞损失、组织损伤和功能缺陷。可以说比身体上的更重要 中枢神经系统损伤的心理影响,可能导致视力丧失、瘫痪或认知功能下降。最近,我们的研究小组使用血管紧张素转换酶(ACE)抑制剂雷米普利(一种FDA批准的药物)对CNS辐射损伤的药理学缓解进行了唯一的研究。值得注意的是,即使在辐射暴露后数周给予雷米普利,也观察到功能和组织病理学评估的损伤减少。该项目基于以下假设:通过促炎介质网络抑制多细胞相互作用引起的氧化应激, 具体的药物治疗。众所周知,有三类药物可抑制氧化应激,其中两类,ACE抑制剂及其受体阻断剂和他汀类药物广泛用于人类各种心血管疾病。该项目旨在解决三类药物的特定治疗作用,ACE抑制剂和受体阻滞剂,他汀类药物和SOD模拟物,在脑损伤的所有阶段,即,急性、早期延迟和晚期延迟反应。其主要目的是证明其有效性,并优化使用药物剂量和给药时间,以减轻和治疗放射性脑损伤。评价终点为认知功能、视觉功能、血脑屏障渗透性MRI以及神经发生、血管和神经胶质细胞的组织病理学和增殖性变化,使用成年大鼠的单次全脑辐射。由于ACE抑制剂和他汀类药物在临床上广泛用于各种心血管疾病,因此拟议研究的阳性结果将很容易在人类中转化。总之,实验研究表明,辐射诱导的CNS损伤是可以治疗的。该项目的目标是将这些实验方法中的一种或多种带入临床实践。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAE HO KIM其他文献

JAE HO KIM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAE HO KIM', 18)}}的其他基金

Mitigating Cutaneous Radiation Injury with CXCR4 Antagonist
使用 CXCR4 拮抗剂减轻皮肤放射损伤
  • 批准号:
    7963624
  • 财政年份:
    2010
  • 资助金额:
    $ 52.02万
  • 项目类别:
Mitigating Cutaneous Radiation Injury with CXCR4 Antagonist
使用 CXCR4 拮抗剂减轻皮肤放射损伤
  • 批准号:
    8125035
  • 财政年份:
    2010
  • 资助金额:
    $ 52.02万
  • 项目类别:
Mitigating and treating radiation-induced CNS injury
减轻和治疗辐射引起的中枢神经系统损伤
  • 批准号:
    7055649
  • 财政年份:
    2005
  • 资助金额:
    $ 52.02万
  • 项目类别:
Suicide Gene and Radiation Therapy Clinical Trials
自杀基因与放射治疗临床试验
  • 批准号:
    6990166
  • 财政年份:
    2004
  • 资助金额:
    $ 52.02万
  • 项目类别:
RADIOTHERAPY OF HSV-TK TRANSDUCED TUMOR BY A-VIRAL AGENT
A病毒剂对HSV-TK转导肿瘤的放射治疗
  • 批准号:
    6130423
  • 财政年份:
    1996
  • 资助金额:
    $ 52.02万
  • 项目类别:
RADIOTHERPY OF HS/TK TRANSDUCED TUMORS BY A VIRAL AGENTS
病毒因子对 HS/TK 转导肿瘤的放射治疗
  • 批准号:
    2748765
  • 财政年份:
    1996
  • 资助金额:
    $ 52.02万
  • 项目类别:
RADIOTHERPY OF HS/TK TRANSDUCED TUMORS BY A VIRAL AGENTS
病毒因子对 HS/TK 转导肿瘤的放射治疗
  • 批准号:
    2458122
  • 财政年份:
    1996
  • 资助金额:
    $ 52.02万
  • 项目类别:
RADIOTHERPY OF HS/TK TRANSDUCED TUMORS BY A VIRAL AGENTS
病毒因子对 HS/TK 转导肿瘤的放射治疗
  • 批准号:
    2106717
  • 财政年份:
    1996
  • 资助金额:
    $ 52.02万
  • 项目类别:
COMBINED BRACHYTHERAPY AND HYPERTHERMIA
近距离治疗和热疗联合治疗
  • 批准号:
    3197900
  • 财政年份:
    1991
  • 资助金额:
    $ 52.02万
  • 项目类别:
COMBINED BRACHYTHERAPY AND HYPERTHERMIA
近距离治疗和热疗联合治疗
  • 批准号:
    3197901
  • 财政年份:
    1991
  • 资助金额:
    $ 52.02万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了